Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Ampio Pharmaceuticals (NY: AMPE )

1.740 USD -0.060 (-3.33%)
Official Closing Price Updated: 8:00 PM EST, Jan 25, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Ampio Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Ampio Pharmaceuticals Ongoing Phase I Clinical Trial for Inhalation Treatment of COVID-19 with Ampion is 55% Enrolled
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced its... 
From PR Newswire
Ampio Provides Update on Clinical Trials for Ampion™ Treatment of COVID-19 Patients
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced an update... 
From PR Newswire
Thinking about buying stock in BioNano Genomics, Ampio Pharmaceuticals, TRACON Pharmaceuticals, eMagin Corp, or Matinas BioPharma?
InvestorsObserver issues critical PriceWatch Alerts for BNGO, AMPE, TCON, EMAN, and MTNB. 
From PR Newswire
Ampio Receives feedback from the FDA on Ampio's Proposed Modifications to the special protocol assessment for Ampion treatment of severe Osteoarthritis of the knee
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today it has... 
From PR Newswire
Thinking about buying stock in CASI Pharmaceuticals, FuelCell Energy, Ampio Pharmaceuticals, Mohawk Group, or Perion Network?
InvestorsObserver issues critical PriceWatch Alerts for CASI, FCEL, AMPE, MWK, and PERI. 
From PR Newswire
Thinking about buying stock in CNS Pharmaceuticals, DermTech, Ampio Pharmaceuticals, Surface Oncology, or Amyris?
InvestorsObserver issues critical PriceWatch Alerts for CNSP, DMTK, AMPE, SURF, and AMRS. 
From PR Newswire
Ampion Demonstrates Safety In COVID-19 Patients And Initiates Global Clinical Trial For Intravenous Ampion
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it has... 
From PR Newswire
Thinking about buying stock in Inseego Corp, Ampio Pharmaceuticals, Marathon Patent Group, Regulus Therapeutics, or BioCryst Pharmaceuticals?
InvestorsObserver issues critical PriceWatch Alerts for INSG, AMPE, MARA, RGLS, and BCRX. 
From PR Newswire
Thinking about buying stock in Nantkwest, Ampio Pharmaceuticals, Arbutus Biopharma, Xeris Pharmaceuticals, or iBio Inc?
InvestorsObserver issues critical PriceWatch Alerts for NK, AMPE, ABUS, XERS, and IBIO. 
From PR Newswire
Ampio Enters into Collaborative Research Agreements to Explore Additional Clinical Indications for its Immunomodulatory Drug, Ampion
Agreements made with (i) Oldest and one of the top children's hospitals in the United States and (ii) Prominent Research Scientist at Vanderbilt University Medical Center 
From PR Newswire
Pelareorep Along With Checkpoint Inhibitors Proving Critically Important for Early Stage Breast Cancer
Tags Featured News
From FinancialNewsMedia.com Newswire for Stock Alerts, Public Company News Alert
Pelareorep Along With Checkpoint Inhibitors Proving Critically Important for Early Stage Breast Cancer
Financialnewsmedia.com News Commentary 
From PR Newswire
Thinking about buying stock in Pfizer, Ampio Pharmaceuticals, Aerpio Pharmaceuticals, Electrameccanica Vehicles, or United Airlines?
InvestorsObserver issues critical PriceWatch Alerts for PFE, AMPE, ARPO, SOLO, and UAL. 
From PR Newswire
Ampio Pharmaceuticals, Inc. to Host its Annual Meeting on December 12, 2020
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today that the Company... 
From PR Newswire
Ampio's Phase I Study For Inhaled Ampion Advances To Completing Enrollment Of COVID-19 Patients With Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that its... 
From PR Newswire
Ampio Updates Regulatory and Clinical Trial Events
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, announced today the... 
From PR Newswire
Ampio's Phase I Study for Inhaled Ampion Advances to 3rd Group of COVID-19 Patients with Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the... 
From PR Newswire
Ampio's Phase I Study For Inhaled Ampion Advances To 2nd Group Of COVID-19 Patients With Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the... 
From PR Newswire
Ampio Pharmaceuticals, Inc. Provides Business Update and Reports Third Quarter 2020 Financial Results
Ampio Pharmaceuticals (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, today, at 4:30pm EST, will... 
From PR Newswire
Ampio Pharmaceuticals, Inc. to Host Conference Call on November 5th
Will Provide Business Update and Review Third Quarter Financial Results 
From PR Newswire
Ampio Begins Phase 1 Clinical Trial of Inhaled Ampion For COVID-19 Patients With Respiratory Distress
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today the... 
From PR Newswire
Ampio Pharmaceuticals, Inc. to Present at the ROTH Capital Healthcare Event "COVID-19 Therapeutics in Development"
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today it will... 
From PR Newswire
Ampio Presents at Roth Capital Partners 2020 MedTech Innovation Forum Focusing on COVID-19 Clinical Trial Activities
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology based therapies for prevalent inflammatory conditions, announced today that the... 
From PR Newswire
Ampio Publication Reports Beneficial Effects of Ampion on Important Transcription Factors in Inflammation
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced the... 
From PR Newswire
Theralink® Technologies Appoints Thomas Chilcott as Chief Financial Officer
Theralink Technologies (OTC: OBMP) ("Theralink" or the "Company"), a molecular profiling company specializing in patented, biomarker assay services that target multiple areas of oncology, today... 
From PR Newswire
Thinking about buying stock in Onconova Therapeutics, Norwegian Cruise Line, Ampio Pharmaceuticals, Delta Air Lines, or Plug Power?
InvestorsObserver issues critical PriceWatch Alerts for ONTX, NCLH, AMPE, DAL, and PLUG. 
From PR Newswire
FDA Grants IND and Approves Clinical Trial Protocol of Inhaled Ampion for COVID-19 Patients with Respiratory Distress
From PR Newswire
Ampion Phase I COVID-19 Patient Trial Results Featured on FOX News (Video)
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that... 
From PR Newswire
Ampio Reports Positive Results for Ampion Treatment in COVID-19 Patients
- Ampion-treated patients showed improvement from severe disease/hospitalization to uninfected/ambulatory on the ordinal scale 
From PR Newswire
Ampio Announces Enrollment Completion for Intravenous ("IV") COVID-19 Clinical Trial & Provides Update on Osteoarthritis of the Knee ("OAK") Clinical Trial
Ampio Pharmaceuticals, Inc. (NYSE American: AMPE), a biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions announces the following: 
From PR Newswire
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.